Lybocent financials
A multi-period view of the public annual-account figures reported for Lybocent, with comparable measures and links to available source documents.
Company overviewRegistry number
0802581859
Fiscal coverage
2024–2025
Public sources
cbso_bulk
Data updated
Jul 29, 2026
Financial evidence
Latest movements for Lybocent
2025 versus 2024
- Operating line
- €12,557
- EBITDA
- €11,970
- Total assets
- €83,274
- Equity
- €18,802
+62.8%
+65.6%
+435.5%
+78.3%
EBITDA margin +95.3% · Equity ratio +22.6%
Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.